| Citation: |
CHEN Chiwei, LIN Mandi, LIU Hao, ZHU Lujun, ZENG Haiping, WANG Zhigang, WANG Jun, CHEN Ming. Risk or Protective Factors of Prostate Cancer Progressing to Castration Resistant Prostate Cancer After Androgen Deprivation Therapy[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 512-516. DOI: 10.3971/j.issn.1000-8578.2020.19.1440
|
To screen the possible risk factors and protective factors for prostate cancer early (in 2 years)progressing to castration resistant prostate cancer (CRPC).
A total of 71 patients who had progressed to CRPC in 2 years were classified as case group and 71 patients without progressing to CRPC in 2 years were classified as control group. Logistic regression analysis and survival analysis were applied to screen the risk or protective factors.
PSA nadir and Time to PSA nadir (TTN) were statistically significant between case group and control group in logistic regression analysis (P < 0.05). Median CRPC occurrence time was 8.29 and 16 months in TTN≤9 months group and TTN > 9 months group, respectively. Median CRPC occurrence time was 12 and 9 months in PSA nadir≤0.2 ng/ml group and PSA nadir > 0.2 ng/ml group, respectively.
TTN may be a protective factor and PSA nadir may be an independent risk factor for prostate cancer early progressing to CRPC. TTN≤9 months and PSA nadir > 0.2 ng/ml are the risk factors of CRPC.
| [1] |
唐志柳, 白洁, 顾丽娜, 等. 2000~2010年我国前列腺癌和乳腺癌流行状况的系统性综述[J].中国肿瘤, 2013, 22(4): 260-265. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzl201304005
Tang ZL, Bai J, Gu LN, et al. Systematic review the epidemic condition of prostate and breast cancer[J]. Zhongguo Zhong Liu, 2013, 22(4): 260-265. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzl201304005
|
| [2] |
韩苏军, 张思维, 陈万青, 等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学, 2013, 18(4): 330-334. doi: 10.3969/j.issn.1009-0460.2013.04.009
Han SJ, Zhang SW, Chen WQ, et al. Trend analysis of morbidity of Chinese prostate cancer[J]. Lin Chuang Zhong Liu Xue, 2013, 18(4): 330-334. doi: 10.3969/j.issn.1009-0460.2013.04.009
|
| [3] |
那彦群, 叶章群, 孙颖浩, 等.中国泌尿外科疾病诊断治疗指南[M].人民卫生出版社, 2014: 61-84.
Na YQ, Ye ZQ, Sun YH, et al. China diagnosis and treatment guidelines of urology disease [M]. People's Medical Publishing House, 2014: 61-84.
|
| [4] |
纪光杰, 黄聪, 宋刚, 等.去势抵抗性前列腺癌进展时间的预测因素分析[J].北京大学学报(医学版), 2017, 49(4): 657-662. doi: 10.3969/j.issn.1671-167X.2017.04.020
Ji GJ, Huang C, Song G, et al. Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy[J]. Beijing Da Xue Xue Bao (Yi Xue Ban), 2017, 49(4): 657-662. doi: 10.3969/j.issn.1671-167X.2017.04.020
|
| [5] |
徐凡, 董柏君, 潘家骅, 等.转移性前列腺癌早期去势抵抗的预测因素分析[J].现代泌尿外科杂志, 2015, 20(2): 80-84. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xdmnwkzz201502003
Xu F, Dong BJ, Pan JH, et al. Early castration prostate cancer:analysis of prognostic factors[J]. Xian Dai Mi Niao Wai Ke Za Zhi, 2015, 20(2): 80-84. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xdmnwkzz201502003
|
| [6] |
孙涛.维、汉前列腺癌患者内分泌治疗敏感时间相关因素分析[D].新疆医科大学, 2016.
Sun T. Analysis of correlation factors on the sensitive time of hormonal therapy for Uygur and Han patients with prostate cancer[D]. Xinjiang Medical University, 2016.
|
| [7] |
王镇伟.雄激素阻断治疗后进展到去势抵抗性前列腺癌时间预测因素分析[D].大连医科大学, 2017.
Wang ZW. Time to Castration resistant prostate cancer after maximal androgen blockade: analysis of prognostic factors[D]. Dalian Medical University, 2017.
|
| [8] |
Teoh JY, Tsu JH, Yuen SK, et al. Association of time to prostate-specific antigen nadir logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with priorprimary androgen deprivation therapy[J]. Asian J Androl, 2017, 19(1): 98-102. http://www.ncbi.nlm.nih.gov/pubmed/26585698
|
| [9] |
Thomas BM, Smith C, Evans J, et al. Time to prostate specific antigen(PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate ancer(CRPC) receiving docetaxel chemotherapy[J]. Med Oncol, 2013, 30(4): 719. http://europepmc.org/abstract/med/24026658
|
| [10] |
Wenisch JM, Mayr FB, Spiel AO, et al. Androgen deprivation decrease prostate specific antigen in the absence of tumor:implications for interpretation of PSA results[J]. Clin Chem Lab Med, 2014, 52(3): 431-436. http://www.ncbi.nlm.nih.gov/pubmed/24423580
|
| [11] |
Benaim EA, Pace CM, ROehrborn CG, et al. Gleason score predicts androgen independent progression after androgen deprivation therapy[J]. Eur Urolo, 2002, 42: 12-17. doi: 10.1016/S0302-2838(02)00238-5
|
| [12] |
郑路.前列腺癌骨转移的相关因素分析[D].新疆医科大学, 2016.
Zheng L. Analysis of related factors of bone metastasis of prostate cancer[D]. Xinjiang Medical University, 2016.
|
| [13] |
欧汝彪, 陈晖, 钟红, 等.前列腺体积和年龄因素对前列腺特异性抗原等指标在前列腺癌筛选中的影响[J].新医学, 2009, 40(2): 83-86. doi: 10.3969/j.issn.0253-9802.2009.02.004
Ou RB, Chen H, Zhong H, et al. Effect of prostate volume and patients age on PSA and other indexs in screening prostate cancer[J]. Xin Yi Xue, 2009, 40(2): 83-86. doi: 10.3969/j.issn.0253-9802.2009.02.004
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: